vesicles that resemble LBs in A549 cells. 12 The overall transport activity, expressed as the fluorescence intensity per vesicle in all measured vesicles is thereby composed of three different parameters:
the volume of the vesicles, the portion of filled vesicles and the fluorescence intensity in filled vesicles.
Mutations in ABCA3 lead to surfactant deficiency and pulmonary diseases like fatal respiratory distress in newborns or chronic interstitial lung disease in children (chILD) and adults. 13, 14 To date, no causal therapies exist to treat patients suffering from lung diseases due to ABCA3 mutations. It is therefore a major task to identify pharmacological modulators for ABCA3 that would allow to treat those diseases.
In cystic fibrosis, a pulmonary disease caused by mutations in the ABC transporter cystic fibrosis transmembrane conductance regulator (CFTR, ABCC7), 15, 16 compounds have successfully been developed, which partially or completely correct the molecular defect in a mutation-specific manner. Misfolding mutations, like the most frequent variation F508del, that lead to impaired processing and trafficking through the cell due to ER retention can be targeted by so called correctors that increase the delivery of CFTR to the cell surface. [17] [18] [19] [20] Functional mutations, like the third-most frequent CFTR variation G551D, that display impaired function but correct processing and localization, can be rescued by potentiators. 17, [20] [21] [22] CFTR potentiators ivacaftor (IVA) and genistein (GEN) lead to an increase in CFTR transport activity at the cell surface by enhancing its open probability (P 0 ).
For ABCA3 we showed that a treatment with correctors rescued processing, trafficking, localization and function of misfolding mutations. 23 Since a lot of ABCA3 mutations are classified as functional mutations, the main goal of this study was to evaluate the effect of potentiators on the lipid transport function of those mutations.
Therefore we analysed three well-described functional ABCA3 mutants, namely N568D in NBD1, T1114M in TMD2 and L1580P in NBD2. [24] [25] [26] We additionally analysed F629L and G667R variations, which were homologous to positions F508 and G550 in CFTR respectively ( Figure 1A and B). G667R is located in the NBD1 conserved ABC signature motif, similarly affected in G551D in CFTR. It was selected because a rare variant has been described in humans in this position. 27 All five mutants showed severely impaired lipid transport function that was rescued by treatment with the CFTR potentiators ivacaftor (IVA) and genistein (GEN) in mutants N568D, F629L and G667R. The results presented here might pave the way for mutation-group specific treatment of pulmonary diseases caused by ABCA3 mutations.
| MATERIAL S AND ME THODS

| Molecular modelling
Structural models of wild-type and mutant ABCA3 were build using phyre2 protein modelling webserver. 28 The model of ABCA3 fulllength in its unbound conformation was build based on the 4.1Å electron microscopy structure of human ABCA1 (pdbid: 5XJY). 29 Solely the NBD1-2 and the TMD1-2 were kept in the final model. 
| Sequence analysis
Protein sequence alignment between ABCA3 and CFTR was performed with the UniProt sequence alignment online tool. 31 F629
and G668 were identified to correspond to F508 and G551 in CFTR ( Figure 1B ). Variations F629L and G667R were identified using the Exome Aggregation Consortium (ExAc) Browser, 27 with G667 corresponding to G550 in CFTR since no mutation was listed for position G668 in ABCA3.
Conservation analysis was performed with ConSurf Server. 32 Initial sequence selection was performed on the Uniref90 database using an E-value threshold of 0.0001. Within this pool, the best 137 ABCA3 sequences were manually selected. Final alignment was performed with the MAFFT-L-INS-i method and scoring was calculated using the Bayesian method.
| Potentiators
Ivacaftor (VX-770, IVA) was purchased from Sellekchem (Munich, Germany). Genistein (GEN) was purchased from Sigma Aldrich (Taufkirchen, Germany). Both substances were dissolved in dimethyl sulphoxide (DMSO, Sigma). 
| Cell culture
| Plasmids
A pT2/HB transposon vector (Addgene, Cambridge, plasmid#26557) was generated, containing hABCA3 cDNA (NM_001089) with corresponding CMV promoter elements fused to a C-terminal HAtag and puromycin resistance gene, as described before. Primer sequences are given in the Supporting Information Materials and Methods Section.
| Transfection and generation of stable cell clones
Transfection of A549 cells using the sleeping beauty transposon system 34 and generation of stable cell clones were performed as described before. 
| Immunofluorescence staining and confocal microscopy
For immunofluorescent stainings, cells were seeded in ibiTreat slides Nuclei were stained by incubation with 0.1 µg/ml 4′,6-diamidin-2- 
| TopFluor-PC transport quantification
Surfactant-like liposomes were prepared and transport of TopFluorlabeled phosphatidylcholine (TopF-PC) into HA-positive vesicles was quantified as described before. 12 In short, TopF-PC contain- 
| RE SULTS
| ABCA3 mutations are predicted to be functional mutations according to an ABCA3 3D model
Three-dimensional structure modelling was performed and molecular consequences of all five mutations were consistently predicted to impair function of the ABCA3 lipid transport activity ( Figure 1 ).
These observations are indicated for each mutation below. Lipid transport activity of F629L mutant was increased to 47%
of WT activity by ivacaftor and 46% by genistein treatment, due to a significant increase of the portion of filled vesicles ( Figure 3A and C).
For all other mutant proteins, a slight yet not significant increase of lipid transport activity upon potentiator treatment was detected.
Potentiators did not influence the processing of ABCA3 as- 
| G667R mutant displayed lower affinity to genistein and was rescued by increased concentrations
Genistein was shown to bind to the LSGGQ signature motif in CFTR. [39] [40] [41] Since G667R is located in this motif in ABCA3
( Figure 1B ), we suggested a decreased affinity of genistein to the mutant protein that might be overcome by higher concentrations of the potentiator. Figure 4A and B) and also the portion of filled vesicles and the volume were slightly also not significantly increased ( Figure 4C and B) .
In L1580P ABCA3 expressing cells, no significant effect of genistein at increased concentrations was detected.
In our experimental setup, concentrations of 5 µmol/L ivacaftor reduced the viability of the cells (data not shown), so no analysis of higher concentrations of ivacaftor on lipid transport in G667R ABCA3 expressing cells was possible. Viability assays showed the toxicity of ivacaftor for the cells ( Figure S4 ).
| D ISCUSS I ON
Functional impairment of ABCA3 due to mutations may lead to fatal or chronic disturbances of ATII cells and surfactant homoeostasis resulting in pulmonary diseases like neonatal respiratory distress syndrome and chronic interstitial lung disease. In the present study, we
showed impaired phospholipid transport function of ABCA3 due to distinct disease causing functional mutations that can be rescued by the CFTR potentiators ivacaftor and genistein for mutations located in the NBD1 of the protein. Since genistein is presumably binding in the LSGGQ motif of NBD1, 41 where the mutation G667R is located, the affinity of the potentiator to the mutant protein is likely to be lowered like shown for G551D in CFTR. 39, 40 For WT ABCA3, genistein treatment exerted potentiating effects up to a concentration of 50 µmol/L and inhibitory effects at higher concentrations resulting in a bell-shaped doseresponse relation like also shown for CFTR. 39, 42, 43 This is explained by the assumption of two binding sites for genistein, one high-affinity site activating the protein and a second low affinity site exerting an inhibitory effect. 41, 43 In G667R This is further supported by the fact that ivacaftor was also ineffective to rescue the L927P CFTR mutant (T1114 is homologous to L935 in CFTR), which is also located in the eighth transmembrane helix and is implicated in conformational changes necessary to open the channel. 47, 48 Furthermore, ivacaftor did not overcome impaired PC secretion activity in a TMD mutant of ABCB4. 49 Residue L1580 is not directly located in the ATP binding site, however its mutation to a proline most likely breaks the helix, in which it is located. This will affect the upstream H-loop, which is also implicated in NBD dimerization and ATP binding. In addition to In this study, we used the A549 cell model stably expressing WT and mutant ABCA3. A limitation of this approach is the current inability to predict the effect of potentiators in patients. On the one hand, there is a lack of information on influences of the patient-specific genetic and environmental background. On the other hand, the impact of overexpression of ABCA3 is unknown. In future studies, those limitations might be overcome by the use of patientspecific primary cell cultures or induced pluripotent stem (iPS) cells.
The optimal model would utilize patient-derived alveolar epithelial type II cells, which are not readily available due to rarity of the patients and difficulties to access the terminal area of the lungs.
Nevertheless, the A549 model is a valuable tool to identify groups of mutations that can be targeted by the same modulator.
Similar to cystic fibrosis, where in vitro studies on Fisher rat thyroid cells expressing rare CFTR mutants were sufficient for the approval of ivacaftor for 23 rare CFTR mutations without need of patient data from clinical trials. 48, 50 Our functional assay using TopF-PC reliably reproduced lipid transport and ATPase activity studies of the mutant proteins performed by Matsumura et al 25, 26 (Table S1 ) and also replicated dose-response relations of genistein in CFTR, 39, 42, 43 making it suitable for high-throughput screens to identify other substances that act as potentiators for ABCA3.
Here we showed that some functional ABCA3 mutations were rescued by the potentiators genistein and ivacaftor. This provides a proof of principle and a first step for the development of pharmacological therapies for interstitial lung diseases caused by ABCA3 mutations, for which currently no treatment is available. 
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